R321
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 61
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.420
- MTORC1_SIGNALING+0.340
- E2F_TARGETS+0.320
- FATTY_ACID_METABOLISM+0.310
- PEROXISOME+0.270
- TGF_BETA_SIGNALING+0.270
- G2M_CHECKPOINT+0.260
- OXIDATIVE_PHOSPHORYLATION+0.260
- MITOTIC_SPINDLE+0.250
- MYC_TARGETS_V1+0.250
Top 10 suppressed
- ANGIOGENESIS-0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- ALLOGRAFT_REJECTION-0.440
- APICAL_JUNCTION-0.440
- MYOGENESIS-0.400
- IL6_JAK_STAT3_SIGNALING-0.390
- COAGULATION-0.370
- WNT_BETA_CATENIN_SIGNALING-0.370
- COMPLEMENT-0.350
- INFLAMMATORY_RESPONSE-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R125 | — | — | 0.896 |
| 2 | TCGA-CU-A3QU-01A-11R-A22U-07 | — | — | 0.885 |
| 3 | SRR1516049 | — | — | 0.882 |
| 4 | DRR168570 | — | — | 0.881 |
| 5 | 1ac3f1b2-5b83-470c-b1d3-d35d813f3e65 | — | — | 0.870 |
| 6 | fd49c74b-2a85-46cd-aaa0-dbd2f1284947 | — | — | 0.867 |
| 7 | R130 | — | — | 0.866 |
| 8 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.861 |
| 9 | MDT-AP-3402 | Med | Medulloblastoma | 0.851 |
| 10 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| PEROXISOME | 0.270 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |